慢病毒转染造血干细胞介导的肿瘤基因治疗的研究进展  

Genetic therapy of the tumor mediated by hematopoietic stem cells transfected by lentivirus vector

作　　者：马巍[1] 吴学元[1] 陈炜[1] 刘广宇[1] 

机构地区：[1]西安交通大学第一医院骨外科,陕西西安710061

出　　处：《现代肿瘤医学》2006年第6期754-757,共4页Journal of Modern Oncology

基　　金：陕西省科技厅攻关项目(编号:2005K09-G12)

摘　　要：肿瘤基因治疗是继手术、放化疗等传统治疗方法之后出现的一种全新的肿瘤治疗方法,并在科研和临床方面取得可喜的进展。如何将肿瘤治疗基因安全高效的转移到人体内,使治疗基因在人体内长期、稳定、高效的表达是当前基因治疗实践中所遇到的重大困难。造血干细胞(hematopoieticstemcells,HSCs)因具有自我更新和定向分化能力,治疗基因转染到造血干细胞内可长期、持续、有效的杀伤肿瘤达到治疗目的。这使的造血干细胞成为基因治疗研究中最令人兴奋的靶细胞。慢病毒载体(lentivirusvector,LV)能感染大部分处于静止期的造血干细胞,因此成为一种有效的感染HSCs和进行基因治疗的工具。本文就慢病毒携带肿瘤治疗基因转染HSCs治疗肿瘤方面做一综述。The genetic therapy of tumor is a bran - new way of treatment after the traditional therapy of surgery, radiotherapy and chemotherapy, and it has made great progress in the research and clinical field. The main difficulty in its practice is how to make the therapeutic genes transfect into the human body efficiently and safely and express endurably, stably and efficiently. The target genes can be transfected to the HSCs （hematopoietic stem cells） and kill the tumor endurably , lastingly and efficiently in these ceils which have the ability to self - renewal and oriented differentiate. Thus the HSCs are the most exciting target ceils in the genetic therapy research.. LV（ lentivirus vector） is an effective implement to infect HSCs and put the genetic therapy into practice as they can infect most of the HSCs in quiescent stage. This article is a review of the LV that transfects target gene into HSCs to treat tumor.

关 键 词：肿瘤基因治疗 造血干细胞 慢病毒载体 分化能力 

分 类 号：R730.5[医药卫生—肿瘤]